Clicky

Bluejay Diagnostics, Inc.(BJDX)

Description: Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Inflammation Allergy Biomarkers Sepsis Chemical Pathology Congestive Heart Failure Allergic Conjunctivitis Conjunctivitis Lyme Disease

Home Page: www.bluejaydx.com

BJDX Technical Analysis

360 Massachusetts Avenue
Acton, MA 01720
United States
Phone: 844 327 7078


Officers

Name Title
Mr. Indranil Dey Pres, CEO & Director
Dr. Jason Cook Chief Technology Officer
Mr. Kenneth R. Fisher CPA Chief Financial Officer
Mr. Kevin Vance Chief Commercial Officer
Mark W. Feinberg Chief Medical Advisor
Dr. Mark W. Feinberg M.D. Chief Medical Advisor

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.6712
Price-to-Sales TTM: 34.8037
IPO Date: 2021-11-10
Fiscal Year End: December
Full Time Employees: 9
Back to stocks